Andrew J. Warmus focuses his practice on domestic mergers and acquisitions, joint ventures and other strategic transactional matters. He has broad experience representing financial sponsors, multinational public companies and private companies in acquisitions and divestitures across multiple industries, including healthcare and life sciences.
Andrew advises buyers and sellers in complex, domestic and cross-border acquisitions, divestitures and strategic transactions often involving complex, multijurisdictional carve-out transactions in regulated industries. Andrew also provides counsel to a number of portfolio companies on a wide range of matters, and builds and leads bespoke teams to deliver commercial solutions.
Represented F45 Training, Inc. in connection with the equity investment by an investor group led by Mark Wahlberg*
Represented Walgreens Co. in connection with the formation of allianceRx Walgreens + Prime, a strategic alliance between Walgreens Co. and Prime Therapeutics creating one of the largest specialty and home delivery pharmacies in the United States*
Represented Fortune Brands Home & Security, Inc. in connection with multiple early-stage investments and commercial arrangements with start-up companies*
Represented SAFRAN S.A. in connection with a strategic joint venture with The Boeing Company*
Represented Abbott Laboratories in the sale of the St. Jude Medical Angio-Seal and FemoSeal vascular closure devices business to Terumo Corporation*
Represented Abbott Laboratories in the divestiture of Alere, Inc.’s Triage MeterPro cardiovascular and toxicology business and BNP Assay business run on Beckman Coulter analyzers*
Represented ARIAD Pharmaceuticals in the divestiture of its European operations to Incyte Corporation*
Represented CommScope in its acquisition of telecom, enterprise and wireless business from TE Connectivity*
Represented Abbott Laboratories in connection with the sale of its non-US developed markets specialty and branded generics business to Mylan Inc. in exchange for an approximately 21% equity interest in Mylan Inc.*
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.